APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antihyperuricemic Agents

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antihyperuricemic Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025190 pages

Choose your research edition.

Industry ResearchAntihyperuricemic Agents Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Antihyperuricemic Agents Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Antihyperuricemic Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antihyperuricemic Agents Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Antihyperuricemic Agents Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Antihyperuricemic Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antihyperuricemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antihyperuricemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antihyperuricemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antihyperuricemic Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antihyperuricemic Agents include Accord Healthcare, ALP Pharm, APOTEX, Casper Pharma, Dr. Reddys Laboratories, Gentec Pharmaceutical Group, Hikma, Indoco Remedies and Ipca Laboratories, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antihyperuricemic Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antihyperuricemic Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antihyperuricemic Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antihyperuricemic Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Antihyperuricemic Agents Segment by Company

Accord Healthcare

ALP Pharm

APOTEX

Casper Pharma

Dr. Reddys Laboratories

Gentec Pharmaceutical Group

Hikma

Indoco Remedies

Ipca Laboratories

Lupin

Medinova

NorthStar Healthcare

Odan Laboratories

Rhea Pharmaceutical

TEIJIN

Waterstone Pharmaceuticals

West Ward Pharmaceuticals

Wockhardt

Zydus Pharmaceuticals

Beijing Jialin Pharmaceutical

Hangzhou Zhuyangxin Pharmaceutical

Jiangsu Hengrui Medicine

Jiangsu Wanbang Biopharmaceuticals

KPC Pharmaceuticals

Mylan

Sun Pharmaceutical

Teva

Tonghua Limin

Takeda Pharmaceuticals

YiChang HEC ChangJiang Pharmaceutical

Antihyperuricemic Agents Segment by Type

Inhibit Uric Acid Production Agents

Promote Uric Acid Excretion Agents

Others

Antihyperuricemic Agents Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Antihyperuricemic Agents Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antihyperuricemic Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antihyperuricemic Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antihyperuricemic Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antihyperuricemic Agents market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antihyperuricemic Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antihyperuricemic Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antihyperuricemic Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antihyperuricemic Agents Industry Trends Table 2. Antihyperuricemic Agents Industry Drivers Table 3. Antihyperuricemic Agents Industry Opportunities and Challenges Table 4. Antihyperuricemic Agents Industry Restraints Table 5. Global Antihyperuricemic Agents Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antihyperuricemic Agents Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antihyperuricemic Agents Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antihyperuricemic Agents Sales Market Share by Manufacturers Table 9. Global Antihyperuricemic Agents Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antihyperuricemic Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antihyperuricemic Agents Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antihyperuricemic Agents Manufacturers, Product Type & Application Table 13. Global Antihyperuricemic Agents Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antihyperuricemic Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Inhibit Uric Acid Production Agents Table 17. Major Manufacturers of Promote Uric Acid Excretion Agents Table 18. Major Manufacturers of Others Table 19. Global Antihyperuricemic Agents Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Antihyperuricemic Agents Sales by Type (2021-2026) & (K Units) Table 21. Global Antihyperuricemic Agents Sales by Type (2027-2032) & (K Units) Table 22. Global Antihyperuricemic Agents Sales Market Share by Type (2021-2026) Table 23. Global Antihyperuricemic Agents Sales Market Share by Type (2027-2032) Table 24. Global Antihyperuricemic Agents Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global Antihyperuricemic Agents Revenue by Type (2021-2026) & (K Units) Table 26. Global Antihyperuricemic Agents Revenue by Type (2027-2032) & (K Units) Table 27. Global Antihyperuricemic Agents Revenue Market Share by Type (2021-2026) Table 28. Global Antihyperuricemic Agents Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Retail Pharmacies Table 30. Major Manufacturers of Online Pharmacies Table 31. Major Manufacturers of Hospital Pharmacies Table 32. Global Antihyperuricemic Agents Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Antihyperuricemic Agents Sales by Application (2021-2026) & (K Units) Table 34. Global Antihyperuricemic Agents Sales by Application (2027-2032) & (K Units) Table 35. Global Antihyperuricemic Agents Sales Market Share by Application (2021-2026) Table 36. Global Antihyperuricemic Agents Sales Market Share by Application (2027-2032) Table 37. Global Antihyperuricemic Agents Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Antihyperuricemic Agents Revenue by Application (2021-2026) & (K Units) Table 39. Global Antihyperuricemic Agents Revenue by Application (2027-2032) & (K Units) Table 40. Global Antihyperuricemic Agents Revenue Market Share by Application (2021-2026) Table 41. Global Antihyperuricemic Agents Revenue Market Share by Application (2027-2032) Table 42. Global Antihyperuricemic Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Antihyperuricemic Agents Sales by Region (2021-2026) & (K Units) Table 44. Global Antihyperuricemic Agents Sales Market Share by Region (2021-2026) Table 45. Global Antihyperuricemic Agents Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Antihyperuricemic Agents Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Antihyperuricemic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 49. North America Antihyperuricemic Agents Sales by Country (2027-2032) & (K Units) Table 50. Europe Antihyperuricemic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 52. Europe Antihyperuricemic Agents Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Antihyperuricemic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Antihyperuricemic Agents Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Antihyperuricemic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Antihyperuricemic Agents Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Antihyperuricemic Agents Sales by Country (2027-2032) & (K Units) Table 59. Global Antihyperuricemic Agents Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Antihyperuricemic Agents Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Antihyperuricemic Agents Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Antihyperuricemic Agents Revenue Market Share by Region (2021-2026) Table 63. Global Antihyperuricemic Agents Revenue Market Share by Region (2027-2032) Table 64. Accord Healthcare Company Information Table 65. Accord Healthcare Business Overview Table 66. Accord Healthcare Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Accord Healthcare Antihyperuricemic Agents Product Portfolio Table 68. Accord Healthcare Recent Development Table 69. ALP Pharm Company Information Table 70. ALP Pharm Business Overview Table 71. ALP Pharm Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. ALP Pharm Antihyperuricemic Agents Product Portfolio Table 73. ALP Pharm Recent Development Table 74. APOTEX Company Information Table 75. APOTEX Business Overview Table 76. APOTEX Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. APOTEX Antihyperuricemic Agents Product Portfolio Table 78. APOTEX Recent Development Table 79. Casper Pharma Company Information Table 80. Casper Pharma Business Overview Table 81. Casper Pharma Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Casper Pharma Antihyperuricemic Agents Product Portfolio Table 83. Casper Pharma Recent Development Table 84. Dr. Reddys Laboratories Company Information Table 85. Dr. Reddys Laboratories Business Overview Table 86. Dr. Reddys Laboratories Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Dr. Reddys Laboratories Antihyperuricemic Agents Product Portfolio Table 88. Dr. Reddys Laboratories Recent Development Table 89. Gentec Pharmaceutical Group Company Information Table 90. Gentec Pharmaceutical Group Business Overview Table 91. Gentec Pharmaceutical Group Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Gentec Pharmaceutical Group Antihyperuricemic Agents Product Portfolio Table 93. Gentec Pharmaceutical Group Recent Development Table 94. Hikma Company Information Table 95. Hikma Business Overview Table 96. Hikma Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Hikma Antihyperuricemic Agents Product Portfolio Table 98. Hikma Recent Development Table 99. Indoco Remedies Company Information Table 100. Indoco Remedies Business Overview Table 101. Indoco Remedies Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Indoco Remedies Antihyperuricemic Agents Product Portfolio Table 103. Indoco Remedies Recent Development Table 104. Ipca Laboratories Company Information Table 105. Ipca Laboratories Business Overview Table 106. Ipca Laboratories Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Ipca Laboratories Antihyperuricemic Agents Product Portfolio Table 108. Ipca Laboratories Recent Development Table 109. Lupin Company Information Table 110. Lupin Business Overview Table 111. Lupin Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Lupin Antihyperuricemic Agents Product Portfolio Table 113. Lupin Recent Development Table 114. Medinova Company Information Table 115. Medinova Business Overview Table 116. Medinova Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Medinova Antihyperuricemic Agents Product Portfolio Table 118. Medinova Recent Development Table 119. NorthStar Healthcare Company Information Table 120. NorthStar Healthcare Business Overview Table 121. NorthStar Healthcare Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. NorthStar Healthcare Antihyperuricemic Agents Product Portfolio Table 123. NorthStar Healthcare Recent Development Table 124. Odan Laboratories Company Information Table 125. Odan Laboratories Business Overview Table 126. Odan Laboratories Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Odan Laboratories Antihyperuricemic Agents Product Portfolio Table 128. Odan Laboratories Recent Development Table 129. Rhea Pharmaceutical Company Information Table 130. Rhea Pharmaceutical Business Overview Table 131. Rhea Pharmaceutical Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Rhea Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 133. Rhea Pharmaceutical Recent Development Table 134. TEIJIN Company Information Table 135. TEIJIN Business Overview Table 136. TEIJIN Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. TEIJIN Antihyperuricemic Agents Product Portfolio Table 138. TEIJIN Recent Development Table 139. Waterstone Pharmaceuticals Company Information Table 140. Waterstone Pharmaceuticals Business Overview Table 141. Waterstone Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Waterstone Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 143. Waterstone Pharmaceuticals Recent Development Table 144. West Ward Pharmaceuticals Company Information Table 145. West Ward Pharmaceuticals Business Overview Table 146. West Ward Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. West Ward Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 148. West Ward Pharmaceuticals Recent Development Table 149. Wockhardt Company Information Table 150. Wockhardt Business Overview Table 151. Wockhardt Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Wockhardt Antihyperuricemic Agents Product Portfolio Table 153. Wockhardt Recent Development Table 154. Zydus Pharmaceuticals Company Information Table 155. Zydus Pharmaceuticals Business Overview Table 156. Zydus Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 157. Zydus Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 158. Zydus Pharmaceuticals Recent Development Table 159. Beijing Jialin Pharmaceutical Company Information Table 160. Beijing Jialin Pharmaceutical Business Overview Table 161. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 162. Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 163. Beijing Jialin Pharmaceutical Recent Development Table 164. Hangzhou Zhuyangxin Pharmaceutical Company Information Table 165. Hangzhou Zhuyangxin Pharmaceutical Business Overview Table 166. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 167. Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 168. Hangzhou Zhuyangxin Pharmaceutical Recent Development Table 169. Jiangsu Hengrui Medicine Company Information Table 170. Jiangsu Hengrui Medicine Business Overview Table 171. Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 172. Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Portfolio Table 173. Jiangsu Hengrui Medicine Recent Development Table 174. Jiangsu Wanbang Biopharmaceuticals Company Information Table 175. Jiangsu Wanbang Biopharmaceuticals Business Overview Table 176. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 177. Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Portfolio Table 178. Jiangsu Wanbang Biopharmaceuticals Recent Development Table 179. KPC Pharmaceuticals Company Information Table 180. KPC Pharmaceuticals Business Overview Table 181. KPC Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 182. KPC Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 183. KPC Pharmaceuticals Recent Development Table 184. Mylan Company Information Table 185. Mylan Business Overview Table 186. Mylan Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 187. Mylan Antihyperuricemic Agents Product Portfolio Table 188. Mylan Recent Development Table 189. Sun Pharmaceutical Company Information Table 190. Sun Pharmaceutical Business Overview Table 191. Sun Pharmaceutical Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 192. Sun Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 193. Sun Pharmaceutical Recent Development Table 194. Teva Company Information Table 195. Teva Business Overview Table 196. Teva Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 197. Teva Antihyperuricemic Agents Product Portfolio Table 198. Teva Recent Development Table 199. Tonghua Limin Company Information Table 200. Tonghua Limin Business Overview Table 201. Tonghua Limin Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 202. Tonghua Limin Antihyperuricemic Agents Product Portfolio Table 203. Tonghua Limin Recent Development Table 204. Takeda Pharmaceuticals Company Information Table 205. Takeda Pharmaceuticals Business Overview Table 206. Takeda Pharmaceuticals Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 207. Takeda Pharmaceuticals Antihyperuricemic Agents Product Portfolio Table 208. Takeda Pharmaceuticals Recent Development Table 209. YiChang HEC ChangJiang Pharmaceutical Company Information Table 210. YiChang HEC ChangJiang Pharmaceutical Business Overview Table 211. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 212. YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Portfolio Table 213. YiChang HEC ChangJiang Pharmaceutical Recent Development Table 214. Key Raw Materials Table 215. Raw Materials Key Suppliers Table 216. Antihyperuricemic Agents Distributors List Table 217. Antihyperuricemic Agents Customers List Table 218. Research Programs/Design for This Report Table 219. Authors List of This Report Table 220. Secondary Sources Table 221. Primary Sources List of Figures Figure 1. Antihyperuricemic Agents Product Image Figure 2. Global Antihyperuricemic Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antihyperuricemic Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Antihyperuricemic Agents Sales (2021-2032) & (K Units) Figure 5. Global Antihyperuricemic Agents Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antihyperuricemic Agents Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Inhibit Uric Acid Production Agents Image Figure 9. Promote Uric Acid Excretion Agents Image Figure 10. Others Image Figure 11. Global Antihyperuricemic Agents Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Antihyperuricemic Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Antihyperuricemic Agents Sales Market Share by Type (2021-2032) Figure 14. Global Antihyperuricemic Agents Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Antihyperuricemic Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Antihyperuricemic Agents Revenue Market Share by Type (2021-2032) Figure 17. Retail Pharmacies Image Figure 18. Online Pharmacies Image Figure 19. Hospital Pharmacies Image Figure 20. Global Antihyperuricemic Agents Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Antihyperuricemic Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Antihyperuricemic Agents Sales Market Share by Application (2021-2032) Figure 23. Global Antihyperuricemic Agents Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Antihyperuricemic Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Antihyperuricemic Agents Revenue Market Share by Application (2021-2032) Figure 26. North America Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Antihyperuricemic Agents Sales Market Share by Country (2021-2032) Figure 28. U.S. Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Antihyperuricemic Agents Sales Market Share by Country (2021-2032) Figure 33. Germany Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Antihyperuricemic Agents Sales Market Share by Country (2021-2032) Figure 40. China Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Antihyperuricemic Agents Sales Market Share by Country (2021-2032) Figure 48. Brazil Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Antihyperuricemic Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Antihyperuricemic Agents Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Antihyperuricemic Agents Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Figure 59. North America Antihyperuricemic Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Figure 61. Europe Antihyperuricemic Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Antihyperuricemic Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Antihyperuricemic Agents Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Antihyperuricemic Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Antihyperuricemic Agents Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Antihyperuricemic Agents Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Inhibit Uric Acid Production Agents
  • Promote Uric Acid Excretion Agents
  • Others
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Accord Healthcare
  • ALP Pharm
  • APOTEX
  • Casper Pharma
  • Dr. Reddys Laboratories
  • Gentec Pharmaceutical Group
  • Hikma
  • Indoco Remedies
  • Ipca Laboratories
  • Lupin
  • Medinova
  • NorthStar Healthcare
  • Odan Laboratories
  • Rhea Pharmaceutical
  • TEIJIN
  • Waterstone Pharmaceuticals
  • West Ward Pharmaceuticals
  • Wockhardt
  • Zydus Pharmaceuticals
  • Beijing Jialin Pharmaceutical
  • Hangzhou Zhuyangxin Pharmaceutical
  • Jiangsu Hengrui Medicine
  • Jiangsu Wanbang Biopharmaceuticals
  • KPC Pharmaceuticals
  • Mylan
  • Sun Pharmaceutical
  • Teva
  • Tonghua Limin
  • Takeda Pharmaceuticals
  • YiChang HEC ChangJiang Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antihyperuricemic Agents Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antihyperuricemic Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antihyperuricemic Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antihyperuricemic Agents Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antihyperuricemic Agents Market Dynamics
  1. 2.1 Antihyperuricemic Agents Industry Trends
  2. 2.2 Antihyperuricemic Agents Industry Drivers
  3. 2.3 Antihyperuricemic Agents Industry Opportunities and Challenges
  4. 2.4 Antihyperuricemic Agents Industry Restraints
3 Antihyperuricemic Agents Market by Manufacturers
  1. 3.1 Global Antihyperuricemic Agents Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antihyperuricemic Agents Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antihyperuricemic Agents Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antihyperuricemic Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antihyperuricemic Agents Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antihyperuricemic Agents Manufacturers, Product Type & Application
  7. 3.7 Global Antihyperuricemic Agents Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antihyperuricemic Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antihyperuricemic Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antihyperuricemic Agents Tier 1, Tier 2, and Tier 3
4 Antihyperuricemic Agents Market by Type
  1. 4.1 Antihyperuricemic Agents Type Introduction
  2. 4.1.1 Inhibit Uric Acid Production Agents
  3. 4.1.2 Promote Uric Acid Excretion Agents
  4. 4.1.3 Others
  5. 4.2 Global Antihyperuricemic Agents Sales by Type
  6. 4.2.1 Global Antihyperuricemic Agents Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Antihyperuricemic Agents Sales by Type (2021-2032)
  8. 4.2.3 Global Antihyperuricemic Agents Sales Market Share by Type (2021-2032)
  9. 4.3 Global Antihyperuricemic Agents Revenue by Type
  10. 4.3.1 Global Antihyperuricemic Agents Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Antihyperuricemic Agents Revenue by Type (2021-2032)
  12. 4.3.3 Global Antihyperuricemic Agents Revenue Market Share by Type (2021-2032)
5 Antihyperuricemic Agents Market by Application
  1. 5.1 Antihyperuricemic Agents Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Antihyperuricemic Agents Sales by Application
  6. 5.2.1 Global Antihyperuricemic Agents Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Antihyperuricemic Agents Sales by Application (2021-2032)
  8. 5.2.3 Global Antihyperuricemic Agents Sales Market Share by Application (2021-2032)
  9. 5.3 Global Antihyperuricemic Agents Revenue by Application
  10. 5.3.1 Global Antihyperuricemic Agents Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Antihyperuricemic Agents Revenue by Application (2021-2032)
  12. 5.3.3 Global Antihyperuricemic Agents Revenue Market Share by Application (2021-2032)
6 Global Antihyperuricemic Agents Sales by Region
  1. 6.1 Global Antihyperuricemic Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antihyperuricemic Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Antihyperuricemic Agents Sales by Region (2021-2026)
  4. 6.2.2 Global Antihyperuricemic Agents Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antihyperuricemic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antihyperuricemic Agents Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antihyperuricemic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antihyperuricemic Agents Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antihyperuricemic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antihyperuricemic Agents Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antihyperuricemic Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antihyperuricemic Agents Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antihyperuricemic Agents Revenue by Region
  1. 7.1 Global Antihyperuricemic Agents Revenue by Region
  2. 7.1.1 Global Antihyperuricemic Agents Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antihyperuricemic Agents Revenue by Region (2021-2026)
  4. 7.1.3 Global Antihyperuricemic Agents Revenue by Region (2027-2032)
  5. 7.1.4 Global Antihyperuricemic Agents Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antihyperuricemic Agents Revenue (2021-2032)
  8. 7.2.2 North America Antihyperuricemic Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antihyperuricemic Agents Revenue (2021-2032)
  11. 7.3.2 Europe Antihyperuricemic Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antihyperuricemic Agents Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antihyperuricemic Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antihyperuricemic Agents Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antihyperuricemic Agents Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Accord Healthcare
  2. 8.1.1 Accord Healthcare Company Information
  3. 8.1.2 Accord Healthcare Business Overview
  4. 8.1.3 Accord Healthcare Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Accord Healthcare Antihyperuricemic Agents Product Portfolio
  6. 8.1.5 Accord Healthcare Recent Developments
  7. 8.2 ALP Pharm
  8. 8.2.1 ALP Pharm Company Information
  9. 8.2.2 ALP Pharm Business Overview
  10. 8.2.3 ALP Pharm Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ALP Pharm Antihyperuricemic Agents Product Portfolio
  12. 8.2.5 ALP Pharm Recent Developments
  13. 8.3 APOTEX
  14. 8.3.1 APOTEX Company Information
  15. 8.3.2 APOTEX Business Overview
  16. 8.3.3 APOTEX Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 APOTEX Antihyperuricemic Agents Product Portfolio
  18. 8.3.5 APOTEX Recent Developments
  19. 8.4 Casper Pharma
  20. 8.4.1 Casper Pharma Company Information
  21. 8.4.2 Casper Pharma Business Overview
  22. 8.4.3 Casper Pharma Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Casper Pharma Antihyperuricemic Agents Product Portfolio
  24. 8.4.5 Casper Pharma Recent Developments
  25. 8.5 Dr. Reddys Laboratories
  26. 8.5.1 Dr. Reddys Laboratories Company Information
  27. 8.5.2 Dr. Reddys Laboratories Business Overview
  28. 8.5.3 Dr. Reddys Laboratories Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Dr. Reddys Laboratories Antihyperuricemic Agents Product Portfolio
  30. 8.5.5 Dr. Reddys Laboratories Recent Developments
  31. 8.6 Gentec Pharmaceutical Group
  32. 8.6.1 Gentec Pharmaceutical Group Company Information
  33. 8.6.2 Gentec Pharmaceutical Group Business Overview
  34. 8.6.3 Gentec Pharmaceutical Group Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Gentec Pharmaceutical Group Antihyperuricemic Agents Product Portfolio
  36. 8.6.5 Gentec Pharmaceutical Group Recent Developments
  37. 8.7 Hikma
  38. 8.7.1 Hikma Company Information
  39. 8.7.2 Hikma Business Overview
  40. 8.7.3 Hikma Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Hikma Antihyperuricemic Agents Product Portfolio
  42. 8.7.5 Hikma Recent Developments
  43. 8.8 Indoco Remedies
  44. 8.8.1 Indoco Remedies Company Information
  45. 8.8.2 Indoco Remedies Business Overview
  46. 8.8.3 Indoco Remedies Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Indoco Remedies Antihyperuricemic Agents Product Portfolio
  48. 8.8.5 Indoco Remedies Recent Developments
  49. 8.9 Ipca Laboratories
  50. 8.9.1 Ipca Laboratories Company Information
  51. 8.9.2 Ipca Laboratories Business Overview
  52. 8.9.3 Ipca Laboratories Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ipca Laboratories Antihyperuricemic Agents Product Portfolio
  54. 8.9.5 Ipca Laboratories Recent Developments
  55. 8.10 Lupin
  56. 8.10.1 Lupin Company Information
  57. 8.10.2 Lupin Business Overview
  58. 8.10.3 Lupin Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Lupin Antihyperuricemic Agents Product Portfolio
  60. 8.10.5 Lupin Recent Developments
  61. 8.11 Medinova
  62. 8.11.1 Medinova Company Information
  63. 8.11.2 Medinova Business Overview
  64. 8.11.3 Medinova Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Medinova Antihyperuricemic Agents Product Portfolio
  66. 8.11.5 Medinova Recent Developments
  67. 8.12 NorthStar Healthcare
  68. 8.12.1 NorthStar Healthcare Company Information
  69. 8.12.2 NorthStar Healthcare Business Overview
  70. 8.12.3 NorthStar Healthcare Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 NorthStar Healthcare Antihyperuricemic Agents Product Portfolio
  72. 8.12.5 NorthStar Healthcare Recent Developments
  73. 8.13 Odan Laboratories
  74. 8.13.1 Odan Laboratories Company Information
  75. 8.13.2 Odan Laboratories Business Overview
  76. 8.13.3 Odan Laboratories Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Odan Laboratories Antihyperuricemic Agents Product Portfolio
  78. 8.13.5 Odan Laboratories Recent Developments
  79. 8.14 Rhea Pharmaceutical
  80. 8.14.1 Rhea Pharmaceutical Company Information
  81. 8.14.2 Rhea Pharmaceutical Business Overview
  82. 8.14.3 Rhea Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Rhea Pharmaceutical Antihyperuricemic Agents Product Portfolio
  84. 8.14.5 Rhea Pharmaceutical Recent Developments
  85. 8.15 TEIJIN
  86. 8.15.1 TEIJIN Company Information
  87. 8.15.2 TEIJIN Business Overview
  88. 8.15.3 TEIJIN Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 TEIJIN Antihyperuricemic Agents Product Portfolio
  90. 8.15.5 TEIJIN Recent Developments
  91. 8.16 Waterstone Pharmaceuticals
  92. 8.16.1 Waterstone Pharmaceuticals Company Information
  93. 8.16.2 Waterstone Pharmaceuticals Business Overview
  94. 8.16.3 Waterstone Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Waterstone Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  96. 8.16.5 Waterstone Pharmaceuticals Recent Developments
  97. 8.17 West Ward Pharmaceuticals
  98. 8.17.1 West Ward Pharmaceuticals Company Information
  99. 8.17.2 West Ward Pharmaceuticals Business Overview
  100. 8.17.3 West Ward Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 West Ward Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  102. 8.17.5 West Ward Pharmaceuticals Recent Developments
  103. 8.18 Wockhardt
  104. 8.18.1 Wockhardt Company Information
  105. 8.18.2 Wockhardt Business Overview
  106. 8.18.3 Wockhardt Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Wockhardt Antihyperuricemic Agents Product Portfolio
  108. 8.18.5 Wockhardt Recent Developments
  109. 8.19 Zydus Pharmaceuticals
  110. 8.19.1 Zydus Pharmaceuticals Company Information
  111. 8.19.2 Zydus Pharmaceuticals Business Overview
  112. 8.19.3 Zydus Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Zydus Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  114. 8.19.5 Zydus Pharmaceuticals Recent Developments
  115. 8.20 Beijing Jialin Pharmaceutical
  116. 8.20.1 Beijing Jialin Pharmaceutical Company Information
  117. 8.20.2 Beijing Jialin Pharmaceutical Business Overview
  118. 8.20.3 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Beijing Jialin Pharmaceutical Antihyperuricemic Agents Product Portfolio
  120. 8.20.5 Beijing Jialin Pharmaceutical Recent Developments
  121. 8.21 Hangzhou Zhuyangxin Pharmaceutical
  122. 8.21.1 Hangzhou Zhuyangxin Pharmaceutical Company Information
  123. 8.21.2 Hangzhou Zhuyangxin Pharmaceutical Business Overview
  124. 8.21.3 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Hangzhou Zhuyangxin Pharmaceutical Antihyperuricemic Agents Product Portfolio
  126. 8.21.5 Hangzhou Zhuyangxin Pharmaceutical Recent Developments
  127. 8.22 Jiangsu Hengrui Medicine
  128. 8.22.1 Jiangsu Hengrui Medicine Company Information
  129. 8.22.2 Jiangsu Hengrui Medicine Business Overview
  130. 8.22.3 Jiangsu Hengrui Medicine Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Jiangsu Hengrui Medicine Antihyperuricemic Agents Product Portfolio
  132. 8.22.5 Jiangsu Hengrui Medicine Recent Developments
  133. 8.23 Jiangsu Wanbang Biopharmaceuticals
  134. 8.23.1 Jiangsu Wanbang Biopharmaceuticals Company Information
  135. 8.23.2 Jiangsu Wanbang Biopharmaceuticals Business Overview
  136. 8.23.3 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Jiangsu Wanbang Biopharmaceuticals Antihyperuricemic Agents Product Portfolio
  138. 8.23.5 Jiangsu Wanbang Biopharmaceuticals Recent Developments
  139. 8.24 KPC Pharmaceuticals
  140. 8.24.1 KPC Pharmaceuticals Company Information
  141. 8.24.2 KPC Pharmaceuticals Business Overview
  142. 8.24.3 KPC Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 KPC Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  144. 8.24.5 KPC Pharmaceuticals Recent Developments
  145. 8.25 Mylan
  146. 8.25.1 Mylan Company Information
  147. 8.25.2 Mylan Business Overview
  148. 8.25.3 Mylan Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Mylan Antihyperuricemic Agents Product Portfolio
  150. 8.25.5 Mylan Recent Developments
  151. 8.26 Sun Pharmaceutical
  152. 8.26.1 Sun Pharmaceutical Company Information
  153. 8.26.2 Sun Pharmaceutical Business Overview
  154. 8.26.3 Sun Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Sun Pharmaceutical Antihyperuricemic Agents Product Portfolio
  156. 8.26.5 Sun Pharmaceutical Recent Developments
  157. 8.27 Teva
  158. 8.27.1 Teva Company Information
  159. 8.27.2 Teva Business Overview
  160. 8.27.3 Teva Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Teva Antihyperuricemic Agents Product Portfolio
  162. 8.27.5 Teva Recent Developments
  163. 8.28 Tonghua Limin
  164. 8.28.1 Tonghua Limin Company Information
  165. 8.28.2 Tonghua Limin Business Overview
  166. 8.28.3 Tonghua Limin Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Tonghua Limin Antihyperuricemic Agents Product Portfolio
  168. 8.28.5 Tonghua Limin Recent Developments
  169. 8.29 Takeda Pharmaceuticals
  170. 8.29.1 Takeda Pharmaceuticals Company Information
  171. 8.29.2 Takeda Pharmaceuticals Business Overview
  172. 8.29.3 Takeda Pharmaceuticals Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  173. 8.29.4 Takeda Pharmaceuticals Antihyperuricemic Agents Product Portfolio
  174. 8.29.5 Takeda Pharmaceuticals Recent Developments
  175. 8.30 YiChang HEC ChangJiang Pharmaceutical
  176. 8.30.1 YiChang HEC ChangJiang Pharmaceutical Company Information
  177. 8.30.2 YiChang HEC ChangJiang Pharmaceutical Business Overview
  178. 8.30.3 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  179. 8.30.4 YiChang HEC ChangJiang Pharmaceutical Antihyperuricemic Agents Product Portfolio
  180. 8.30.5 YiChang HEC ChangJiang Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antihyperuricemic Agents Value Chain Analysis
  2. 9.1.1 Antihyperuricemic Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antihyperuricemic Agents Production Mode & Process
  6. 9.2 Antihyperuricemic Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antihyperuricemic Agents Distributors
  9. 9.2.3 Antihyperuricemic Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst